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impairments of memory and concentration, along with
mental slowing. This cognitive decline, which is often
accompanied by motor disorders, has been termed AIDS
dementia complex (ADC), or more recently HIV-1-
associated cognitive/motor complex.’ Most patients with
ADC are severely immunosuppressed and have already
been diagnosed with AIDS/ Although the pathogenesis of
the syndrome is only partly understood, a large body of
evidence points to a central role of HIV-1 itself. This
notion is also supported by the clinical efficacy of
antiretroviral treatment.3
Shortly after the introduction of zidovudine in the late
1980s, there was a major decline in the incidence of
ADC;4 ADC has become a rare disease in patients on
continued zidovudine treatment.2 In addition to its
prophylactic efficacy, zidovudine has therapeutic efficacy
in patients with ADC.’ CSF-markers of central nervous
system HIV-1 infection may decline with zidovudine
use,6,7 and the frequency of HIV-1-related
neuropathological abnormalities has been reduced by
zidovudine.8-1O An increase in frequency of ADC has lately
been observed in a group of HIV-1-infected individuals in
London, among whom the number of patients taking
zidovudine diminished in the past few years (J Catalan,
personal communication). From all these data one can
conclude that zidovudine is a central nervous system
protective drug in the treatment of HIV-1." 11
What about the neuroprotective efficacy of other
nucleoside analogues? Didanosine improved
neurocognitive functioning in a small group of children
with AIDS,12 but it did not prevent the development of
ADC in adults with advanced HIV-1 infection.’3 Clinical
neurological data on patients receiving zalcitabine,
lamivudine, stavudine, and protease-inhibitors are not
available yet. CSF penetration of these drugs varies
widely, with CSF/plasma ratios of 0-6 for zidovudine, 0-2
for didanosine and zalcitabine, 0-06 for lamivudine, and
0-4 for stavudine. Although CSF penetration cannot be
equated with clinical efficacy, drugs that do not penetrate
into the CNS are unlikely to be very effective in
preventing neurological deterioration.
Additional neuroprotection might be achieved by drugs
that do not inhibit viral replication but interfere with
other steps in the pathogenesis of ADC. Thus
pentoxifylline inhibits production and effects of TNF-a,
memantine blocks the action of toxins acting at the
N-methyl-D-aspartate receptor, nimodipine is a calcium-
channel blocker, and peptide-T is a neurotrophic peptide.
Several of these drugs are on the point of entering clinical
trials. A small unpublished study (AIDS Clinical Trial
Group [ACTG] 162) with nimodipine failed to show
clinical efficacy.
Based on preliminary analyses of ACTG 175 and
Delta, presented recently in San Francisco and
Copenhagen, respectively,14 one could envisage combined
regimens becoming standard treatment in HIV-1
infection. To prevent the development of ADC,
combination regimens should include at least one
neuroprotective drug. All the evidence strongly favours
the use of zidovudine for this purpose. However,
zidovudine-resistant CSF and brain isolates have already
been reported, and some patients are zidovudine
intolerant. 14,15 Consequently, more drugs are needed,
preferably both antiretrovirals and adjunctive secondary
treatments. Effort should be put into the development of
these drugs, followed by early CSF-pharmacokinetic
studies and clinical trials with potential neuroprotective
compounds in patients with ADC. Neurological
monitoring for early signs of ADC in patients
participating in ongoing and future clinical trials with
antiretrovirals will provide us with crucial clinical data as
well. In this way, we remain able to treat and prevent one
of the most distressing complications of HIV-1 infection.
Peter Portegies
Department of Neurology, Academic Medical Centre, University of
Amsterdam, Amsterdam, Netherlands
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Exit trans fatty acids
From now on Dutch margarine manufacturers will state
the trans fatty acid content of their products on the label.
In addition, the trans content of margarines and spreads
will be reduced to less than 5%, and for many products it
may drop below 1% within the next year. These
innovations will affect other countries as well, although it
is not yet clear what will happen in the USA. Certain US
manufacturers sell effectively trans-free spreads and some
product reformulation is occurring; however, the majority
view of the US industry is that allegations against trans
fats are exaggerated.’ 1
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Small amounts of trans fatty acids are present in butter
and cheese and in the body fat of ruminants but most of
the trans content of foods arises during the hardening of
oils. This hardening process has been a mainstay of the
edible fats industry ever since it started to produce
margarine as a replacement for butter.2 Butter consists
largely of saturated fatty acids, which are hard; the
replacement thus needed to be firm, but the oils available
were mostly rich in cis-unsaturated fatty acids and fluid.
The solution was found in partial hardening or
hydrogenation; this converts part of the cis-unsaturates
into higher melting point saturated and trans-unsaturated
fatty acids. Partial hydrogenation spurred the growth of
an industry which now provides much of the visible and
invisible fats that we eat, including those in many baked
goods and fast foods.
Although health effects of trans fatty acids were
occasionally questioned, extensive toxicological testing
uncovered no adverse effects.3 Discussion started in 1990
when trans fatty acids were reported to raise serum low-
density lipoprotein (LDL) and lower high-density
lipoprotein (HDL) cholesterol concentrations in
volunteers.4 Subsequent studies confirmed the effect on
LDL and, though less consistently, on HDL.5 Trans fatty
acids also raise plasma triglyceride and lipoprotein(a)
concentrations,6,7 a hereditary risk factor for
cardiovascular disease that is otherwise little affected by
diet. Prospective studies also showed associations between
trans fatty acid intake and subsequent coronary disease.8,9
In such studies a high intake of trans could be merely an
indicator of an unhealthy lifestyle; however, the rise in
LDL and fall in HDL cholesterol seen in metabolic trials
make a cause-and-effect relation credible. Some
epidemiological studies found no association,"," but
confidence intervals were wide enough to embrace the
increase in coronary risk seen in the US investigations. 8,9
As a result of the changes in the composition of food
fats now underway, the average Dutchman will be eating
4 g less of trans fatty acids per day than he or she did
10-15 years ago. These 4 g will be replaced by 2 g of
saturated fat, 1 g of stearic acid (also saturated, but with
little effect on LDL), and 1 g of cis-unsaturated fat.
Together this should produce a fall in LDL cholesterol of
about 0-05 mmol/L, which should lower coronary risk by
2% or so. In addition, HDL should rise by 0-02 mmol/L,
so the total fall in coronary disease incidence could reach
5% even without counting the effect on lipoprotein(a).
Lifestyle changes tend to benefit the well-educated and
wealthy more than the poor, and to widen the health gap
between the social classes; this one, however, may
especially benefit the poor because they may be major
consumers of cheap fats and fast foods. Producers of fats
and oils may be in for some turmoil, but consumers
should be the winners; they may gain a modest rise in
HDL and drop in LDL without having to lift a finger.
Martijn B Katan
Department of Human Nutrition, Agricultural University, Wageningen,
Netherlands
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Learning from stories&mdash;The Lancet’s Case
Reports
Clinicians learn from anecdotes-stories they heard at
medical school, stories they tell each other, and stories
their patients tell them. This is an efficient way to grasp
new knowledge-even the most obscure hints and
warnings can be made memorable if tagged to real people
and actual events. This week we start a section of peer-
reviewed Case Reports, an opportunity for clinicians to
relay the sort of clinical anecdote they might tell
colleagues during a morning coffee break. We expect
younger clinicians, whose daily involvement with patient
care is greater than that of their chiefs, to be an especially
fertile source of good stories.
There are, however, several rules to be observed. The
report occupies one page, has a table or figure, and has no
more than five references. This leaves about 600 words of
text, to be in three paragraphs: case presentation;
investigations, treatment, and outcome; and discussion.
There should be no more than four authors, one of whom
was in clinical charge of the patient when the events took
place.
Potential authors must ask themselves: why do we wish
to tell Lancet readers about this case? Our answer is that
your report must have a striking message: a description of
a new treatment, adverse effect of medication, evidence
that might suggest a new mechanism for a disease
process, or a new intervention. The message may not be
new but it should be of sufficient practical importance to
bear repeating. Case Reports are designed to provide
readers concerned more with patient care than laboratory
research an opportunity to display the rich variety of
clinical medicine. We look forward to your response.
John Bignall, Richard Horton
The Lancet, London, UK
